Millennium Management’s Ovid Therapeutics OVID Stock Holding History

Millennium Management’s Portfolio OVID Stock Details OVID Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$3.32M	Buy	1,496,518 +157,053	+12%	+$281K	﹤0.01%	3377
2025 Q4	$2.18M	Buy	1,339,465 +353,172	+36%	+$544K	﹤0.01%	3862
2025 Q3	$1.28M	Sell	986,293 -66,041	-6%	-$57.2K	﹤0.01%	4420
2025 Q2	$347K	Buy	+1,052,334	New	+$317K	﹤0.01%	5121
2024 Q3	–	Sell	-78,024	Closed	-$60K	–	6375
2024 Q2	$60K	Sell	78,024 -67,941	-47%	-$189K	﹤0.01%	5394
2024 Q1	$445K	Buy	+145,965	New	+$488K	﹤0.01%	4891
2023 Q2	–	Sell	-272,916	Closed	-$704K	–	6535
2023 Q1	$704K	Buy	272,916 +131,212	+93%	+$311K	﹤0.01%	4381
2022 Q4	$264K	Sell	141,704 -88,460	-38%	-$151K	﹤0.01%	5175
2022 Q3	$424K	Sell	230,164 -14,046	-6%	-$29.4K	﹤0.01%	5102
2022 Q2	$525K	Sell	244,210 -207,856	-46%	-$502K	﹤0.01%	4913
2022 Q1	$1.42M	Buy	452,066 +66,299	+17%	+$209K	﹤0.01%	4181
2021 Q4	$1.24M	Sell	385,767 -27,124	-7%	-$92.9K	﹤0.01%	4205
2021 Q3	$1.39M	Sell	412,891 -352,759	-46%	-$1.29M	﹤0.01%	4324
2021 Q2	$2.99M	Buy	+765,650	New	+$3.02M	﹤0.01%	3439
2021 Q1	–	Sell	-254,046	Closed	-$587K	–	6364
2020 Q4	$587K	Buy	254,046 +217,739	+600%	+$1.01M	﹤0.01%	4077
2020 Q3	$208	Sell	36,307 -486,289	-93%	-$3.25M	﹤0.01%	4045
2020 Q2	$3.85M	Buy	522,596 +123,638	+31%	+$578K	0.01%	1995
2020 Q1	$1.19M	Buy	398,958 +79,121	+25%	+$267K	﹤0.01%	2359
2019 Q4	$1.33M	Buy	319,837 +218,876	+217%	+$691K	﹤0.01%	2857
2019 Q3	$327K	Sell	100,961 -247,014	-71%	-$561K	﹤0.01%	3514
2019 Q2	$644K	Buy	+347,975	New	+$621K	﹤0.01%	3066
2019 Q1	–	Sell	-22,286	Closed	-$54K	–	4238
2018 Q4	$54K	Sell	22,286 -68,947	-76%	-$315K	﹤0.01%	3609
2018 Q3	$517K	Buy	91,233 +76,153	+505%	+$577K	﹤0.01%	3241
2018 Q2	$118K	Sell	15,080 -44,264	-75%	-$380K	﹤0.01%	3630
2018 Q1	$420K	Buy	+59,344	New	+$480K	﹤0.01%	3079
2017 Q3	–	Sell	-18,443	Closed	-$193K	–	3769
2017 Q2	$193K	Buy	+18,443	New	+$241K	﹤0.01%	3205

Other funds holding OVID

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

ACM

ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

SVCM

Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Millennium Management's OVID Position: Q1 2026 in Review

Millennium Management increased its Ovid Therapeutics (OVID) stake by 12% in Q1 2026, buying an estimated $281K and bringing the position to 1,496,518 shares worth $3.32M. The position accounts for ﹤0.01% of the portfolio, ranked #3377.

Millennium Management first reported a position in OVID in Q2 2017 and has held it in 26 quarters since. The position peaked at $3.85M in Q2 2020. 103 funds tracked by Wall St. Rank hold OVID as of Q1 2026.

Millennium Management held 1,496,518 shares of Ovid Therapeutics worth $3.32M as of Q1 2026.
Millennium Management bought 157,053 Ovid Therapeutics shares in Q1 2026, an estimated $281K.
Ovid Therapeutics made up ﹤0.01% of Millennium Management's portfolio in Q1 2026, its #3377 holding.
Millennium Management first reported a position in Ovid Therapeutics in Q2 2017 and has held it in 26 quarters since.
Millennium Management's Ovid Therapeutics position peaked at $3.85M in Q2 2020.
103 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q1 2026.

Based on Millennium Management's 13F filing for Q1 2026, filed 15 May 2026.